Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Improving Outcome in Subarachnoid Hemorrhage with Nadroparine
2018-000790-79Phase 4Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2021
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of nadroparin in subarachnoid hemorrhage (SAH) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: 30-day mortality. Started Jun 2021; status: active.
02
Drugs
nadroparin
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on 2018-000790-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000790-79.